Patients in a clinical trial at Massachusetts General Hospital last week received their first doses of an experimental vaccine that keeps most nicotine from entering the brain, The Boston Globe reported.
By late summer, Pfizer Inc. said it expects to begin selling a medication that partially blocks a receptor that seems to be involved in smoking addiction. Another drug under development might "dampen" areas of the brain involved in craving, thus helping smokers quit without gaining much weight, The Globe said.
"For the first time in 10 years, we have completely new approaches for smoking cessation, and there is hope that the new drugs, because they better target the brain's addiction response, could prove more effective than current treatments," said Dr. Nancy Rigotti, director of the hospital's Tobacco Research and Treatment Center.
The National Institutes of Health says of the 44 million Americans who smoke, about 70 percent want to quit and 40 percent really try. But in a given year, fewer than 5 percent of would-be quitters succeed in kicking the habit.
Copyright 2006 by United Press International
Related stories:
Genetic region linked to a 5 times higher lung cancer risk
A narrow region on chromosome 15 contains genetic variations strongly associated with familial lung cancer, says a study conducted by scientists at Washington University School of Medicine in St. Louis and other institutions in the United States and the United Kingdom.
Research suggests that cigarettes' power may not be in nicotine itself
There may be a very good reason why coffee and cigarettes often seem to go hand in hand. A Kansas State University psychology professor's research suggests that nicotine's power may be in how it enhances other experiences. For a smoker who enjoys drinking coffee, the nicotine may make a cup of joe even better. And that may explain why smoking is so hard to quit.
Newly-defined factors may prevent postpartum smoking relapse
Although many women quit smoking during pregnancy to protect their unborn children from the effects of cigarettes, half of them resume the habit within a few months of giving birth.
If your first cigarette gave you a buzz and you now smoke, a gene may be to blame
Anyone who has ever tried smoking probably remembers that first cigarette vividly. For some, it brought a wave of nausea or a nasty coughing fit. For others, those first puffs also came with a rush of pleasure or "buzz."
Tobacco industry manipulated cigarette menthol content to recruit new smokers among young people
Menthol cigarette brands have been rising in popularity with adolescents, and the highest use has been among younger, newer smokers. Researchers at Harvard School of Public Health (HSPH) explored tobacco industry manipulation of menthol levels in specific brands and found a deliberate strategy to recruit and addict young smokers by adjusting menthol to create a milder experience for the first time smoker. Menthol masks the harshness and irritation of cigarettes, allowing delivery of an effective dose of nicotine, the addictive chemical in cigarettes. These milder products were then marketed to the youngest potential consumers.
Smoking cessation therapies more effective than placebos
Six treatments for smoking cessation perform better than placebos — including varenicline (Chantix®), recently approved for use in Canada — states a team of researchers from McGill University and the University of Montreal in an article published in
CMAJ.
Genetic variations put youth at higher risk for lifetime of tobacco addiction
Common genetic variations affecting nicotine receptors in the nervous system can significantly increase the chance that European Americans who begin smoking by age 17 will struggle with lifelong nicotine addiction, according to researchers at the University of Utah and their colleagues at University of Wisconsin-Madison. The study, published in the July 11, 2008 issue of
PLoS Genetics, highlights the importance of public health efforts to reduce the number of youth who begin smoking.
Guidelines for care of elderly patients ignored
Guidelines for the treatment of older patients with respiratory conditions are routinely ignored. Research published today in the open access journal
BMC Health Services Research shows that recommended treatments are given to only a small minority of eligible patients.
